AIA Group Ltd Buys 2,959 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

AIA Group Ltd raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 27.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,600 shares of the biopharmaceutical company’s stock after buying an additional 2,959 shares during the quarter. AIA Group Ltd’s holdings in Regeneron Pharmaceuticals were worth $9,688,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. State Street Corp raised its stake in Regeneron Pharmaceuticals by 1.3% during the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after purchasing an additional 61,277 shares in the last quarter. Loomis Sayles & Co. L P lifted its stake in shares of Regeneron Pharmaceuticals by 33.4% in the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company’s stock valued at $1,122,168,000 after purchasing an additional 393,997 shares during the last quarter. Amundi boosted its holdings in shares of Regeneron Pharmaceuticals by 45.8% in the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock worth $1,138,074,000 after purchasing an additional 487,489 shares during the period. Norges Bank purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $802,036,000. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 695,799 shares of the biopharmaceutical company’s stock valued at $495,639,000 after acquiring an additional 22,538 shares during the period. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on REGN. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. Canaccord Genuity Group initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Finally, Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $637.36 on Monday. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a market cap of $69.68 billion, a PE ratio of 16.65, a P/E/G ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a 12 month low of $629.02 and a 12 month high of $1,211.20. The stock has a fifty day moving average price of $683.88 and a 200-day moving average price of $795.57.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same period last year, the business posted $11.86 earnings per share. The firm’s revenue was up 10.3% compared to the same quarter last year. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.55%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.